Serum high-mobility-group box 1 as a biomarker and a therapeutic target during respiratory virus infections
PublisherAmerican Society for Microbiology
MetadataShow full item record
AbstractHost-derived “danger-associated molecular patterns” (DAMPs) contribute to innate immune responses and serve as markers of disease progression and severity for inflammatory and infectious diseases. There is accumulating evidence that generation of DAMPs such as oxidized phospholipids and high-mobility-group box 1 (HMGB1) during influenza virus infection leads to acute lung injury (ALI). Treatment of influenza virus-infected mice and cotton rats with the Toll-like receptor 4 (TLR4) antagonist Eritoran blocked DAMP accumulation and ameliorated influenza virus-induced ALI. However, changes in systemic HMGB1 kinetics during the course of influenza virus infection in animal models and humans have yet to establish an association of HMGB1 release with influenza virus infection. To this end, we used the cotton rat model that is permissive to nonadapted strains of influenza A and B viruses, respiratory syncytial virus (RSV), and human rhinoviruses (HRVs). Serum HMGB1 levels were measured by an enzyme-linked immunosorbent assay (ELISA) prior to infection until day 14 or 18 post-infection. Infection with either influenza A or B virus resulted in a robust increase in serum HMGB1 levels that decreased by days 14 to 18. Inoculation with the live attenuated vaccine FluMist resulted in HMGB1 levels that were significantly lower than those with infection with live influenza viruses. RSV and HRVs showed profiles of serum HMGB1 induction that were consistent with their replication and degree of lung pathology in cotton rats. We further showed that therapeutic treatment with Eritoran of cotton rats infected with influenza B virus significantly blunted serum HMGB1 levels and improved lung pathology, without inhibiting virus replication. These findings support the use of drugs that block HMGB1 to combat influenza virus-induced ALI. IMPORTANCE Influenza virus is a common infectious agent causing serious seasonal epidemics, and there is urgent need to develop an alternative treatment modality for influenza virus infection. Recently, host-derived DAMPs, such as oxidized phospholipids and HMGB1, were shown to be generated during influenza virus infection and cause ALI. To establish a clear link between influenza virus infection and HMGB1 as a biomarker, we have systematically analyzed temporal patterns of serum HMGB1 release in cotton rats infected with nonadapted strains of influenza A and B viruses and compared these patterns with a live attenuated influenza vaccine and infection by other respiratory viruses. Towards development of a new therapeutic modality, we show herein that blocking serum HMGB1 levels by Eritoran improves lung pathology in influenza B virus-infected cotton rats. Our study is the first report of systemic HMGB1 as a potential biomarker of severity in respiratory virus infections and confirms that drugs that block virus-induced HMGB1 ameliorate ALI. Copyright 2018 Patel et al.
SponsorsThis work was supported by NIH grants AI123371 (S.N.V.) and AI125215 (S.N.V. and J.C.G.B.).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85046417699&doi=10.1128%2fmBio.00246-18&partnerID=40&md5=8dbb38481f93417b995c98ff37a03769; http://hdl.handle.net/10713/9093
- Influenza "Trains" the Host for Enhanced Susceptibility to Secondary Bacterial Infection.
- Authors: Shirey KA, Perkins DJ, Lai W, Zhang W, Fernando LR, Gusovsky F, Blanco JCG, Vogel SN
- Issue date: 2019 May 7
- Novel strategies for targeting innate immune responses to influenza.
- Authors: Shirey KA, Lai W, Patel MC, Pletneva LM, Pang C, Kurt-Jones E, Lipsky M, Roger T, Calandra T, Tracey KJ, Al-Abed Y, Bowie AG, Fasano A, Dinarello CA, Gusovsky F, Blanco JC, Vogel SN
- Issue date: 2016 Sep
- The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge.
- Authors: Younan P, Ramanathan P, Graber J, Gusovsky F, Bukreyev A
- Issue date: 2017 Apr 25
- Induction of high-mobility group Box-1 in vitro and in vivo by respiratory syncytial virus.
- Authors: Manti S, Harford TJ, Salpietro C, Rezaee F, Piedimonte G
- Issue date: 2018 May
- A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
- Authors: Rostad CA, Stobart CC, Gilbert BE, Pickles RJ, Hotard AL, Meng J, Blanco JCG, Moin SM, Graham BS, Piedra PA, Moore ML
- Issue date: 2016 Aug 15